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BACKGROUND: The femoral artery is the most common access route for cerebral angiog-
raphy and neurointerventional procedures. Complications of the transfemoral approach
include groin hemorrhages and hematomas, retroperitoneal hematomas, pseudoa-
neurysms, arteriovenous fistulas, peripheral artery occlusions, femoral nerve injuries, and
access-site infections. Incidence rates vary among different randomized and nonran-
domized trials, and the literature lacks a comprehensive review of this subject.
OBJECTIVE: To gather data from 16 randomized clinical trials (RCT) and 17 nonrandomized
cohort studies regarding femoral access-site complications for a review paper. We also
briefly discuss management strategies for these complications based on the most recent
literature.
METHODS: A PubMed indexed search for all neuroendovascular clinical trials, retro-
spective studies, and prospective studies that reported femoral artery access-site compli-
cations in neurointerventional procedures.
RESULTS: The overall access-site complication rate in RCTs is 5.13%, while in in non-RCTs,
the rate is 2.78%. The most common complication in both groups is groin hematoma
followed by access-site hemorrhage and femoral pseudoaneurysm. On the other hand,
wound infection was the least common complication.
CONCLUSION: The transfemoral approach in neuroendovascular procedures holds risk for
several complications. This reviewwill allow further studies to compare access-site compli-
cations between the transfemoral approach and other alternative access sites, mainly the
transradial approach, which is gaining a lot of interest nowadays.
KEYWORDS: Neuroendovascular, Femoral artery, Groin Hematoma, Femoral artery pseudoaneurysm
Operative Neurosurgery 19:353–363, 2020 DOI: 10.1093/ons/opaa096
S ince the old use of interventional methodsin the diagnosis and treatment of certaincerebral vascular disorders and stroke,
the femoral artery has been the preferred access
point for the introduction of catheters in the
diagnosis and treatment of certain cerebral
vascular disorders and stroke.1-3 However,
the transfemoral approach has been associated
with a wide array of access-site complications,
ABBREVIATIONS: AV, arteriovenous; CI, confidence
interval; OR, odds ratio; RCT, randomized clinical
trial; TAVR, transcatheter aortic valve replacement;
UCG, ultrasound-guided compression; VCD,
vascular closure device
OperativeNeurosurgery Speaks! Audio abstracts available for
this article at www.operativeneurosurgery-online.coms.
ranging in severity from minor complications
requiring minimal treatment to life-threatening
complications requiring aggressive, life-saving
surgical interventions. The most common
access-site complication is groin hematoma,
which may vary in size, while one of the
most serious complications is retroperitoneal
hematoma, which may lead to hemorrhagic
shock and death if not quickly diagnosed and
treated.2-5 Among other complications are
access-site hemorrhages, femoral artery dissec-
tions and pseudoaneurysms, arteriovenous (AV)
fistulas, peripheral artery occlusions, femoral
nerve injuries, and access-site infections.2 Many
studies have reported various incidence rates
of these complications. While the literature
regarding access-site complications in coronary
interventional procedures is well published,
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publications pertaining to a comprehensive review of access-site
complications are lacking for neuroendovascular procedures. In
this article, we review the literature, including randomized clinical
trials, retrospective and prospective cohorts, and certain case
reports to provide a systematic review that summarizes incidence
rates as well as management strategies for access-site complica-
tions related to the transfemoral approach in neurointerventional
procedures.
METHODS
Using PubMed database, we performed a literature search without
time limitations for all articles using different combinations of the
terms transfemoral, neurointervention, neuroendovascular, interventional
neurology, and femoral artery. Articles were then classified as randomized
clinical trials (RCTs) and non-RCTs. Abstracts were screened to
determine if the study matches our requirements, mainly being related
to neurointerventional procedures. Then, full texts were read in depth
to determine whether access-site complications were discussed and if
incidence data were available. Articles were searched for adverse events,
complications, and outcomes in the text, tables, or supplementary
material. Articles that did not provide data about the incidence rates of
access-site complications were excluded. For RCTs, the website clinical-
trials.gov was also searched for publicly available results that included
data about adverse events and access-site complications. RCTs with no
data in published articles or through clinicaltrials.gov were excluded.
Additionally, case reports of rare complications were discussed in a
subsection in the discussion.
Incidence rates were calculated by dividing the number of occur-
rences of each access-site complication by the total number of patients
who underwent a neurointerventional procedure using the transfemoral
approach. If one patient underwent multiple independent procedures,
that patient was counted twice in the total population. The total
incidence rate of access-site complications for each study is calculated
by adding all incidents of access-site complications divided by the total
number of patients. The average incidence rate of a certain complication
among multiple studies is calculated by adding the individual number of
incidents of that complication in all studies divided by the total number
of patients only from studies that reported that complication. Studies that
frankly report no incidents of that particular complication are included
in the total population, while those that do not report the complication
are not included. By excluding these studies from the total population,
we overcome the bias from selective reporting among studies. Due to the
nature of the manuscript, institutional review board approval and patient
consent were not sought.
RESULTS
Study Selection
Our search on PubMed found 30 RCTs and 54 non-RCTs
of various interventional procedures, while the search on clini-
caltrials.gov gave us 29 RCTs all related to neurointerventional
procedures. A total of 19 RCTs were eliminated as duplicates
between the 2 searches. Out of the remaining 40 RCTs, only
16 published data about access-site complications in the trans-
femoral approach and were included in our review. Out of
the 54 non-RCTs, 25 were eliminated at the level of title and
abstract screening either because they are related to cardio-
vascular procedures or because the management was medical,
not requiring an endovascular procedure, whether diagnostic or
interventional. Out of the remaining 29 non-RCTs, 12 were
excluded after full-text reading due to the lack of data regarding
access-site complications. The remaining 17 non-RCTs were
included in our review. In total, we reviewed 16 RCTs and 17
non-RCTs reporting access-site complication rates (Figure 1).
Additionally, 5 non-RCTs tackling the use of different vascular
closure devices (VCDs) have been separately included in our
study.
Study Characteristics
Among the 16 RCTs, 10 were related to stroke management.
These were IMS-II, IMS-III, ESCAPE, EXTEND-IA,
REVASCAT, RIVER JAPAN, SWIFT, THRACE, STAR,
and SWIFT-PRIME. Two RCTs (PUFS and PFLEX) and 1
registry (The Buenos Aires Experience) were related to the use
of pipeline device for the treatment of cerebral aneurysms. One
RCT (ENACT) was related to the use of coiling in treating
cerebral aneurysm, and 2 RCTs (CREST and RADCAR) were
related to carotid artery stenting. Excluded RCTs were MR
CLEAN, MR RESCUE, THERAPY, SYNTHESIS, PISTE,
ASTER, DAWN, TREVO, ADAPT, IntrePED, PREMIER,
PITA, ASPIRe, MATRIX, TEAM, ISAT, SAMMPRIS, ATENA,
CLARITY, WEB-IT, WEBCAST 1, WEBCAST 2, SAPPHIRE,
and ARUBA.
From the 17 non-RCTs included in our study, 7 were related
to diagnostic cerebral angiography, 2 were related to cerebral
aneurysm coiling, 2 were related to the use of flow diverters to
treat cerebral aneurysms, 1 was related to carotid artery stenting,
1 was related to intraarterial chemotherapy delivery, 1 was related




Access-site hemorrhage is a relatively common complication of
interventional procedures using the transfemoral approach and
is considered a leading cause of groin hematomas as well as
retroperitoneal hematomas. Risk factors include use of anticoag-
ulation, insufficient manual compression, and early ambulation.
For the sake of this review, we are defining access-site hemor-
rhage as bleeding from the puncture site without including
contained subcutaneous and retroperitoneal hematomas, as these
are described in separate sections. Seven RCTs report incidents of
groin hemorrhage at rates ranging from 0.78% to 2.61% with an
average of 2.06%, while one non-RCT reports an incidence rate
of 0.59% (Table 1).6-13
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FIGURE 1. The PRISMA diagram summarizing the systematic process used to identify, screen, and include articles analyzed in this
review.
Groin Hematoma
Groin hematoma is the most common complication when
using the femoral artery as an access point in both cardiac and
neurointerventional procedures.3,5,14 Groin hematomas occur
shortly after sheath removal due to failure to control bleeding
from the femoral artery. Risk factors include obesity, use of antico-
agulants, large sheaths, early ambulation, and peripheral vascular
disease.15 It is believed that puncturing below the femoral bifur-
cation as well as poor hemostatic techniques increase the risk of
developing a groin hematoma (Figure 2A).2,15
A total of 12 RCTs reported incidence rates of groin
hematomas between 0.23% and 10.68% with an average of
2.49%, 6-10,12,13,16-20 while non-RCTs reported an incidence rate
of 0.03% to 8.1% with an average of 2.89%.5,14,21-29 Differences
in occurrence rates are partly due to the differences in defining
what constitutes a hematoma. Additionally, some studies only
reported hematomas that are larger than a certain size threshold.
The ESCAPE and REVASCAT trials reported incidence rates of
groin hematoma as high as 9.09% and 10.68%, respectively, while
rates where as low as 0.63% and 0.99% in the CREST and STAR
trials, respectively (Tables 1 and 2).7,13,17,20
The literature regarding the use of VCDs to reduce the risk of
groin hematomas compared to manual compression is variable. A
prospective multicenter registration study by Sato et al30 showed
a significant decrease in incidence rates of groin hematomas
when AngioSeal STS Plus VCD (Terumo) is used vs manual
compression (5.04% vs 34.55%, P-value < .001). Moreover,
hemostasis time was significantly shorter in the VCD group than
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FIGURE 2. A, Femoral hematoma; B, retroperitoneal hematoma; C, arterial pseudoaneurysm; D, arterial dissection;
E, femoral artery occlusion; F, arteriovenous fistula.
in the manual compression group (4.4 vs 150.7 min, P < .001).
On the other hand, incidence rates in 5 non-RCTs reporting groin
hematoma as a complication of the transfemoral approach while
using VCDs ranged between 0.49% and 5.04% with an average
rate of 1.38% (Table 3).30-34
Retroperitoneal Hematoma
Retroperitoneal hematoma, a relatively rare complication of
femoral puncture, develops either due to an uncontrolled groin
hematoma that expands in size or a femoral puncture above the
level of the inguinal ligament (Figure 2B).4,15 It is considered







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































one of the most serious and difficult-to-diagnose complica-
tions. Symptoms are nonspecific and may include suprainguinal
tenderness and fullness (most common), severe back and lower
quadrant abdominal pain, and lower extremity pain. Patients may
also develop hypotension that may require blood transfusions or
urgent surgical intervention.4,35
From the reviewed 40 RCTs, 8 reported the incidence of
retroperitoneal hemorrhage ranging from 0.32% to 1.77% with
an average of 0.57% (Table 1).6,8-10,12,13,36,37 Four non-RCTs
reported incidence rates between 0.03% and 5% with an average
of 0.11% (Table 2).11,23,38,39 However, it is worth noting that
2 of these studies with incidence rates of 4.33% and 5% have
a relatively low total number of enrolled subjects of 22 and 20,
respectively, and only one incidence of retroperitoneal hematoma
in each, which accounted for the relatively high incidence rate.
Although relatively rare, retroperitoneal hematoma is a serious
complication that may lead to death if not treated properly.
The management of retroperitoneal hematoma is mainly conser-
vative for hemodynamically stable with intensive care unit obser-
vation, fluid resuscitation, blood transfusion, and reversal of
anticoagulation. In unresponsive cases, further intervention is
warranted, with preference for percutaneous interventional proce-
dures over surgery.35,40,41 Options include embolization by
coiling, gelatin, and/or polyvinyl alcohol. Other options include
balloon tamponade of the common femoral artery and balloon
catheter delivery of intra-arterial thrombin. Surgical intervention
is entertained if less invasive procedures fail.42
Femoral Artery Pseudoaneurysm and Dissection
Femoral artery pseudoaneurysm is a known but uncommon
complication of interventional procedures, especially via the
transfemoral approach. A pseudoaneurysm is a hematoma with
persistent communication with the artery, and it is usually
limited to the area surrounding the common femoral artery
(Figure 2C).43 Although not always present, a differentiating
aspect of femoral pseudoaneurysms from other groin hematomas
is the presence of pulsation due to the persistent communi-
cation between the pseudoaneurysm and the artery.44 A femoral
puncture below the bifurcation is a risk factor.2,3,43 Other risk
factors include advanced age, obesity, gender (female > male),
use of anticoagulants, and lower platelet count.3
Six RCTs report incidence rates of femoral pseudoaneurysms
between 0.23% and 2.04% with an average of 0.61%
(Table 1).6,7,9,20,45,46 The incidence rate in 7 non-RCTs
ranged between 0.03% and 3.23% with an average of 0.19%
(Table 2).5,11,21,23,25,28,29
On the other hand, femoral artery dissection is an injury to the
vessel wall leading to the disruption of its layers without complete
rupture (Figure 2D). Arterial dissection leads to blood flow distur-
bance and may result in arterial occlusion. Three non-RCTs
report incidence rates of femoral or iliac artery dissection between
0.1% and 0.27%, with an average rate of 0.14% (Table 2).14,22,47
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The management of femoral pseudoaneurysms is usually
conservative. Observation plays an important role until a certain
size threshold. The widely used threshold is 3 cm. Another
approach is ultrasound-guided compression (UGC) of the
pseudoaneurysm neck to block its blood flow for an average of
30 min while maintaining femoral artery blood flow. Stasis of
blood in the pseudoaneurysm leads to its thrombosis. Another
approach with higher success rate is duplex-guided thrombin
injection, in which thrombin is injected in the aneurysm sac.
Surgical intervention is preserved for large pseudoaneurysms with
superimposed skin necrosis, infection, or nerve compression.3
Peripheral Arterial Occlusion
Many factors contribute to arterial occlusion in the peripheral
circulation after transfemoral catheterization, including arterial
stenosis, thrombosis, and dissection (Figure 2D and 2E).
Symptoms include lower limb pain, claudication, cold limb, or
pale color of lower extremity. Symptoms may appear within 24 h
postcatheterization but can also be delayed or appear only
after long-distance ambulation. In severe cases, lower extremity
ischemia may occur requiring aggressive interventional or surgical
treatment.
Peripheral artery occlusion is a relatively rare complication
of the transfemoral approach in neurointerventional procedures.
Three RCTs report incidence rates between 0.23% and 2.04%,
with an average rate of 0.5% (Table 1).6,9,45 Four non-RCTs
report incidence rates between 0.05% and 0.93% with an average
of 0.12% (Table 2).23-25,27 Reported cases included 1 popliteal
artery and 1 iliac artery thrombosis, while the other cases were
unspecified. Higher incidence rates of arterial occlusion ranging
between 0.14% and 6.86% were reported when VCDs were used
for hemostasis (Table 3).1,31 Corley et al48 reported a case of
right common femoral artery occlusion in a 26-yr-old female
undergoing a transfemoral interventional procedure for AVM
embolization. A 6F AngioSeal closure device was used to close
the arteriotomy. The patient had the typical symptoms, and right
common femoral artery occlusion was confirmed by radiology.
Intraoperatively, it was found that the AngioSeal device was
occluding the artery.
AV Fistula
An AV fistula is an abnormal communication between an
artery and a vein (Figure 2F).43 AV fistula formation is a rare
complication of femoral artery catheterization. A puncture below
the femoral bifurcation at the superficial femoral artery is a risk
factor.2,49 Other risk factors include arterial hypertension, female
gender, left groin puncture, and mode and intensity of anticoag-
ulation. AV fistulas lead to left-to-right hemodynamic shunting,
which may reduce blood flow in the downstream vascular bed and
may lead to cardiac failure if left untreated.50
None of the 40 reviewed RCTs reported any case of AV fistula,
while 3 non-RCTs reported incidence rates between 0% and
0.27% with an average rate of 0.07% (Table 2).5,25,47
FIGURE 3. Anatomic diagram showing the femoral vein medially
in blue, femoral artery in red, and femoral nerve laterally in yellow.
The management of AV fistulas comprises observation in most
asymptomatic cases.51 Other techniques include UGC, endovas-
cular embolization, or stent placement and surgery. Indications
for intervention include fistulas that do not heal spontaneously
after 4 wk, progressive enlargement, steal syndrome, venous
hypertension, and heart failure.50,51
Femoral Nerve Injury
The femoral nerve enters the thigh through the femoral triangle
lateral to the femoral artery separated from it by continuous
iliopectineal fascia (Figure 3). Due to the multiple manipulations
in the vicinity of the femoral artery, the femoral nerve is at risk
of compression injury. It manifests as pure sensory symptoms
including pain, paresthesia, and sensory loss. Additionally, the
injury may affect the anterior, medial, and lateral cutaneous
branches of the femoral nerve.52
Two RCTs, SWIFT and RADCAR, reported incidence rates
between 0% and 0.88% with an average rate of 0.41%
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TABLE 4. Minor vs Major Complications in the Different Study
Groups
Complication type
Minor n/N (%) Major n/N (%) P value
RCTs 116/2847 (4.07%) 25/2719 (0.92%) <.0001
Non-RCTs 979/34 414 (2.84%) 71/33 729 (0.21%) <.0001
Non-RCTs with VCDs 67/3272 (2.05%) 27/3272 (0.83%) <.0001
(Table 1).9,12 Qureshi et al52 reported 4 incidents in 270 patients
(1.48%). Usually, symptoms resolve in a period between 1 wk
and 2 mo. Treatment is only symptomatic to relieve pain and
paresthesia.
Access-Site Infection
Surgical site infection is a common complication of all invasive
procedures, especially with the introduction of permanent foreign
bodies. In neurointerventional procedures, groin infection is a
rare but serious complication, especially with the use of femoral
artery closure devices. In 2 RCTs, IMS-III and SWIFT, the
incidence rates were 0.23% and 0.88%, respectively, with an
average of 0.37%. The use of VCDs was not specified in these
trials.6,9 On the other hand, non-RCTs reported incidence rates
between 0% and 2.15%, with an average rate of 0.04%, without
specifying whether VCDs were used or not.5,21,23,25,27,53 In non-
RCTs where VCDs were used at the femoral arteriotomy sites, the
incidence rates ranged between 0% and 0.84% with an average
rate of 0.23% (Table 3).30,31,33,34,54
To prevent procedure-associated infections, the Centers for
Disease Control (CDC) recommends the use of sterile techniques
in catheterization procedures. Prophylactic use of antibiotics is
not recommended unless the patient is immunocompromised
or a definite wound contamination is suspected during the
procedure.55
Minor vs Major Complications
Access-site-related complications can be categorized as minor
vs major complication. The former includes groin hematoma
and groin hemorrhage, while the latter includes retroperi-
toneal hematomas, AV fistulae, femoral artery pseudoaneurysms,
femoral artery dissection, femoral nerve injury, arterial occlusion,
and wound infection. Table 4 shows the distribution of complica-
tions between these 2 groups in both RCTs and non-RCTs. In all
study groups, the incidence rate of minor complications is signifi-
cantly higher than that of major complications (P-value< .0001).
The Use of Ultrasound Guidance
Several studies have investigated the role of ultrasound
guidance in reducing transfemoral access-site complications. One
study by Dudeck et al56 showed a significant decrease in time
to arterial puncture and number of attempts for successful
puncturing only in patients with weak femoral pulse or leg
circumference >60 cm. Another recently published randomized
controlled trial (SURF) showed that there was no difference in
the complication rates between standard and ultrasound guidance
(P = .76). However, ultrasound guidance reduced mean access
time (93 vs 111 s; P = .009), attempts (1.47 vs 1.9; P < .0001),
and venipuncture (4.1% vs 9.2%; P < 0.0001) and improved
first-pass success (73% vs 59.7%; P = .0001).57 On the other
hand, a single-center retrospective cohort study on 387 patients
undergoing transcatheter aortic valve replacement (TAVR) found
that the routine use of ultrasound in transfemoral TAVR was
associated with significant reductions in access-related vascular
and bleeding complications (odds ratio [OR] = 0.42 [95% CI,
0.25-0.70; P < .01]).58 Another recent meta-analysis of 5 RCTs
found that ultrasound guidance significantly improves time to
access (weighted mean difference: 24.90 min, 95% CI 12.41-
37.38), first-pass success rate (OR 2.97; 95% CI 1.49-5.92), and
total complication rate (OR 0.42, 95%CI 0.23-0.77) but did not
have any significant influence on the incidence rate of individual
complications like groin hematoma, retroperitoneal hematoma,
or pseudoaneurysm.59
Access-Site Complications in Cardiovascular and Other
Interventional Procedures
Before we end our discussion, it is important to review the
literature in this matter relating to cardiovascular and other inter-
ventional procedures. Several studies reported incidence rates of
access-site complications in transfemoral catheterization ranging
from 1% to 10%.60-62 Compared to the transradial approach,
transfemoral access had a higher overall rate of access-site compli-
cations in the ACUITY trial (3.7 vs 1.4%; P < .0001). This
trial also showed that the rates of bleeding complications are also
higher in the transfemoral approach (4.5 vs 1.9%; P < .0001).
Moreover, the rate of pseudoaneurysm was also significantly
higher in the transfemoral approach (0.6 vs 0.2%; P= .006).63,64
Additionally, the MATRIX trial showed a significant decrease in
bleeding complication in the transradial approach (1.6 vs 2.3%;
P = .013).64,65 On the other hand, the RIVAL trial did not show
significant differences in terms of primary or secondary endpoints
between radial and femoral approaches.64,66 A meta-analysis of
12 RCTs by Agostoni et al61 concluded that the transradial
approach was significantly superior to femoral access in terms of
the risk of entry site complications in cardiovascular diagnostic
and interventional procedures (0.3% vs 2.8%; OR 0.20, 95% CI
0.09-0.42; P < .0001).
Limitations
One of the limitations faced during our study is the differ-
ences in the definitions of access-site complications among
different trials, along with the difference in the threshold for
reporting these complications. This difference may lead to an
underestimation of the incidence rates in some studies due to
underreporting when thresholds are higher. Another limitation
is that some studies were only interested in reporting specific
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complications without the others, which led us to exclude their
population when calculating the average incidence rates, thus
leading to a smaller total population.Moreover, amajor limitation
is the lack of studies that specifically target access-site compli-
cations in neurointerventional procedures. Studies found in the
literature mention access-site complications in terms of incidence
only, without providing specific patient information like age,
anticoagulation status, present comorbidities, or previous inter-
ventions at the same site. Those studies also fail to provide details
about the technique used, sheath size, and level of heparinization
or anticoagulation. Due to the lack of this data, we were only able
to present the data mostly as a systematic review.
CONCLUSION
The transfemoral approach in neuroendovascular procedures
holds risk for several complications, including groin hematoma
and hemorrhage (most common), retroperitoneal hematoma,
AV fistula, femoral artery pseudoaneurysm, peripheral arterial
occlusion, femoral nerve injury, and surgical wound infection
(least common). The literature lacks a comprehensive review
of all these complications, specifically in the neuroendovascular
field. This review will allow further studies to compare access-
site complications between the transfemoral approach and other
alternative routes, mainly the transradial, which is gaining a lot of
interest nowadays.
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